$22M is nothing if you don't spend it correctly, a lot of biotech start-up I've invest in have done CR for $20M and managed to use it for 3-4 years but mind you they don't have expenditure of $6-8M per quarter which has only happened when AHZ was "trying" to get ADAPT to the market, hopefully with this "transformational" change, management can control their expenditure to $4M.
do not advertise external links.au/...ocel-and-vascucel-for-362-million-904705.html
$22M is nothing if you don't spend it correctly, a lot of...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.25 |
Change
-0.250(1.61%) |
Mkt cap ! $322.3M | |||
| Open | High | Low | Value | Volume |
| $15.50 | $15.50 | $14.80 | $140.4K | 9.315K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 297 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.25 | 1300 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |